{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:01:01Z","timestamp":1793113261911,"version":"4.5.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jfma.2025.05.007","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:26:38Z","timestamp":1748219198000},"page":"S49-S54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"S1","title":["Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis"],"prefix":"10.1016","volume":"124","author":[{"given":"Ru-Yin","family":"Hsu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-Yun","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Jen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Cheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7180-3607","authenticated-orcid":false,"given":"Tzung-Dau","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5278-3540","authenticated-orcid":false,"given":"Hsien-Li","family":"Kao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jung","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2449-9072","authenticated-orcid":false,"given":"Hung-Ju","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jfma.2025.05.007_bib1","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1016\/S0140-6736(14)60685-1","article-title":"Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people","volume":"383","author":"Rapsomaniki","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.05.007_bib2","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1161\/CIRCULATIONAHA.115.020752","article-title":"Low systolic blood pressure and vascular mortality among more than 1 million Korean adults","volume":"133","author":"Yi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib3","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib4","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib5","first-page":"225","article-title":"2022 guidelines of the taiwan society of Cardiology and the taiwan hypertension society for the management of hypertension","volume":"38","author":"Wang","year":"2022","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jfma.2025.05.007_bib6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0140-6736(21)00590-0","article-title":"Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.05.007_bib12","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1001\/jama.2016.7050","article-title":"Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged \u226575 Years: a randomized clinical trial","volume":"315","author":"Williamson","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jfma.2025.05.007_bib8","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa2111437","article-title":"Trial of intensive blood-pressure control in older patients with hypertension","volume":"385","author":"Zhang","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib9","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib10","first-page":"67","article-title":"2019 Chinese guideline for the management of hypertension in the elderly","volume":"16","author":"Hua","year":"2019","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib77","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.jacc.2011.01.008","volume":"57","author":"Aronow","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib78","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting\u2013enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients","volume":"342","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib27","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib28","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","article-title":"The Japanese society of hypertension guidelines for the management of hypertension (JSH 2019)","volume":"42","author":"Umemura","year":"2019","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jfma.2025.05.007_bib54","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.05.007_bib59","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib64","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1097\/00132586-200208000-00043","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"46","author":"Wiklund","year":"2002","journal-title":"Surv Anesthesiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib65","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib66","doi-asserted-by":"crossref","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR\/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 200;283:1295\u20131302.","DOI":"10.1001\/jama.283.10.1295"},{"key":"10.1016\/j.jfma.2025.05.007_bib52","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian enalapril survival study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib53","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.accreview.2003.10.014","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting enzyme inhibitors: the CHARM-alternative trial","volume":"13","author":"Granger","year":"2004","journal-title":"ACC Curr J Rev"},{"key":"10.1016\/j.jfma.2025.05.007_bib60","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1161\/01.CIR.100.23.2312","article-title":"Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group","volume":"100","author":"Packer","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib61","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jfma.2025.05.007_bib62","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib63","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib55","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib56","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1161\/CIRCULATIONAHA.112.110536","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations","volume":"126","author":"Rogers","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib74","article-title":"Antihypertensive therapies in moderate or severe aortic stenosis: a systematic review and meta-analysis","volume":"10","author":"Jonathan","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jfma.2025.05.007_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2015.04.083","article-title":"Beta-blockers can improve survival in medically-treated patients with severe symptomatic aortic stenosis","volume":"190","author":"Andrea","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib7","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1901281","article-title":"Final report of a trial of intensive versus standard blood-pressure control","volume":"384","author":"Lewis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib11","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41371-021-00494-8","article-title":"Intensive blood pressure treatment in coronary artery disease: implications from the Systolic Blood Pressure Intervention Trial (SPRINT)","volume":"36","author":"Zang","year":"2022","journal-title":"J Hum Hypertens"},{"issue":"36","key":"10.1016\/j.jfma.2025.05.007_bib82","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC)","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib15","article-title":"Elderly patients with coronary artery disease","volume":"16","author":"Nakamura","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"10.1016\/j.jfma.2025.05.007_bib16","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib17","first-page":"285","article-title":"2020 focused update of the 2012 guidelines of the taiwan society of Cardiology for the management of ST-segment elevation myocardial infarction","volume":"36","author":"Li","year":"2020","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.jfma.2025.05.007_bib20","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1002\/phar.2624","article-title":"Renin-angiotensin-aldosterone system inhibitors and major cardiovascular events and acute kidney injury in patients with coronary artery disease","volume":"41","author":"Sud","year":"2021","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jfma.2025.05.007_bib18","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib19","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib21","article-title":"AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease","volume":"2023","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib22","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/ehf2.13715","article-title":"Long-term impact of \u03b2-blocker in elderly patients without myocardial infarction after percutaneous coronary intervention","volume":"9","author":"Fukase","year":"2022","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jfma.2025.05.007_bib23","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/gerona\/gly191","article-title":"Patient-important adverse events of \u03b2-blockers in frail older adults after acute myocardial infarction","volume":"74","author":"Zullo","year":"2019","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jfma.2025.05.007_bib14","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American heart association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.coph.2013.01.008","article-title":"Calcium antagonists in the treatment of coronary artery disease","volume":"13","author":"Cooper-DeHoff","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jfma.2025.05.007_bib25","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00508-013-0395-2","article-title":"Benefits and pitfalls of cardiovascular medication in seniors","volume":"125","author":"Kubesova","year":"2013","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.jfma.2025.05.007_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.586183","article-title":"What is the ideal blood pressure treatment target for primary prevention and management of atrial fibrillation?","volume":"7","author":"Meng","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib29","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40885-019-0123-y","article-title":"2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations","volume":"25","author":"Kim","year":"2019","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib30","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jacc.2018.05.076","article-title":"Ideal blood pressure in patients with atrial fibrillation","volume":"72","author":"Kim","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib31","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1093\/europace\/euac059","article-title":"Effects of intensive blood pressure control on cardiovascular and cognitive outcomes in patients with atrial fibrillation: insights from the SPRINT trial","volume":"24","author":"Jiang","year":"2022","journal-title":"Europace"},{"key":"10.1016\/j.jfma.2025.05.007_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ahj.2016.05.001","article-title":"Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF Trial","volume":"178","author":"Vemulapalli","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002015","article-title":"Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) tria","volume":"4","author":"Rao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jfma.2025.05.007_bib35","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1161\/HYPERTENSIONAHA.122.19810","article-title":"Home blood pressure can predict the risk for stroke\/bleeding events in elderly patients with nonvalvular atrial fibrillation from the ANAFIE registry","volume":"79","author":"Kario","year":"2022","journal-title":"Hypertension"},{"key":"10.1016\/j.jfma.2025.05.007_bib36","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41440-023-01361-4","article-title":"Anticoagulant therapy and home blood pressure-associated risk for stroke\/bleeding events in elderly patients with non-valvular atrial fibrillation: the sub-cohort study of ANAFIE registry","volume":"46","author":"Kario","year":"2023","journal-title":"Hypertens Res"},{"issue":"36","key":"10.1016\/j.jfma.2025.05.007_bib83","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib37","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.phrs.2017.10.007","article-title":"Atrial fibrillation and arterial hypertension","volume":"128","author":"Kallistratos","year":"2018","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jfma.2025.05.007_bib38","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2004.10.068","article-title":"Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIFE) study","volume":"45","author":"Wachtell","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib39","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1097\/HJH.0b013e3282f35c67","article-title":"Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial","volume":"26","author":"Schmieder","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib40","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib41","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1161\/01.CIR.0000072793.81076.D4","article-title":"Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials","volume":"107","author":"Vermes","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib42","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ahj.2005.06.036","article-title":"Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"152","author":"Ducharme","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jfma.2025.05.007_bib43","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/1755-5922.12073","article-title":"Effect of telmisartan on atrial fibrillation recurrences in patients with hypertension: a systematic review and meta-analysis","volume":"32","author":"Pan","year":"2014","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jfma.2025.05.007_bib44","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/ajh.2008.217","article-title":"Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation","volume":"21","author":"Fogari","year":"2008","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6628469","article-title":"Angiotensin receptor blocker and calcium channel blocker preventing atrial fibrillation recurrence in patients with hypertension and atrial fibrillation: a meta-analysis","author":"Ma","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"10.1016\/j.jfma.2025.05.007_bib46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCEP.111.965178","article-title":"Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial","volume":"5","author":"Goette","year":"2012","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib47","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.cjco.2021.04.014","article-title":"Effect of perindopril on atrial fibrillation recurrence and burden: results of the Canadian trial of atrial fibrillation (CTAF)-2","volume":"3","author":"Rivard","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.jfma.2025.05.007_bib48","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40885-023-00234-9","article-title":"The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib49","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1111\/jch.14004","article-title":"Hypertension, heart failure, and frailty in older people: a common but unclear situation","volume":"22","author":"Camafort","year":"2020","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib50","unstructured":"Belgium D, Spain A, de Italy G. The task force for the management of arterial hypertension of the European society of Cardiology (ESC) and the European society of hypertension (ESH) ."},{"key":"10.1016\/j.jfma.2025.05.007_bib51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/jch.12094","article-title":"Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years","volume":"15","author":"Wei","year":"2013","journal-title":"J Clin Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib57","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib80","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jamacardio.2017.5365","article-title":"Systolic blood pressure and outcomes in patients with heart failure with preserved ejection fraction","volume":"3","author":"Tsimploulis","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jfma.2025.05.007_bib81","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jchf.2017.08.015","article-title":"Reverse J-curve relationship between on-treatment blood pressure and mortality in patients with heart failure","volume":"5","author":"Lee","year":"2017","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jfma.2025.05.007_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-32684-9","article-title":"Clinical characteristics and outcomes in the very elderly patients hospitalized for acute heart failure: importance of pharmacologic guideline adherence","volume":"8","author":"Sung","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jfma.2025.05.007_bib69","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1097\/HJH.0000000000002426","article-title":"Hypertension in aortic stenosis: a focused review and recommendations for clinical practice","volume":"38","author":"Saeed","year":"2020","journal-title":"J Hypertens"},{"key":"10.1016\/j.jfma.2025.05.007_bib70","doi-asserted-by":"crossref","first-page":"5553","DOI":"10.3390\/jcm10235553","article-title":"Arterial hypertension in aortic valve stenosis: a critical update","volume":"10","author":"Basile","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jfma.2025.05.007_bib71","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ehjci\/jew013","article-title":"Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study","volume":"18","author":"Lionel","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.jfma.2025.05.007_bib72","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/ehjcvp\/pvaa040","volume":"7","author":"Costantino","year":"2021","journal-title":"European Heart Journal - Cardiovascular Pharmacotherapy"},{"key":"10.1016\/j.jfma.2025.05.007_bib73","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCULATIONAHA.115.021213","article-title":"Assessing optimal blood pressure in patients with asymptomatic aortic valve stenosis: the Simvastatin Ezetimibe in Aortic Stenosis Study (SEAS)","volume":"134","author":"Nielsen","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jfma.2025.05.007_bib75","article-title":"Metoprolol reduces hemodynamic and metabolic overload in asymptomatic aortic valve stenosis patients","volume":"10","author":"Nils","year":"2017","journal-title":"Circulation: Cardiovascular Imaging"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625002189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T06:14:25Z","timestamp":1752732865000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625002189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":80,"alternative-id":["S0929664625002189"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.05.007","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}